VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15

Publication | Closed Access

VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study

DOI

Citations

References

2022

Year

L. Paz-Ares, E O’Brien, M. Mauer, Urania Dafni, Kersti Oselin, Libor Havel, Emilio Esteban, Dolores Isla, Alex Martínez‐Martí, Martin Faehling,

Annals of Oncology

MedicineClinical TrialsAdjuvant ChemotherapyImmune Checkpoint InhibitorPharmacotherapyVersus PlaceboComplete ResectionCancer TreatmentOncologyRadiation OncologyLung CancerHealth Sciences